Norway should exclude J&J, AstraZeneca vaccination scheme: Panel | Coronavirus pandemic News

Eight cases of severe coordination in Norway were linked to the AstraZeneca vaccine and four of those recipients were killed, the commission says.

Norway’s COVID-19 vaccine, carried out by AstraZeneca and Johnson & Johnson, should be excluded from its inoculation program because of the risk of rare but harmful side effects, a government-appointed commission said on Monday.

However, volunteers should be allowed to take both vaccines, emphasizing the importance of dispelling doubts about the vaccine.

Norway canceled the spread of the AstraZeneca vaccine on March 11 after a small number of inoculated young people had a small number of blood clots, bleeding and platelets.

The Norwegian Institute of Public Health (FHI) asked on April 15 to completely cancel the AstraZeneca shot, but the government sought the advice of its committee on both this and the J&J shot, which, despite being a European Medicines Agency in Norway, has not been used. (EMA) approval.

Explaining its recommendations, the commission said eight cases of severe coagulation in Norway have been linked to the AstraZeneca vaccine, killing four of those recipients.

“Emphasis must be placed on maintaining confidence in the national vaccination scheme so that the population can be established with multiple rounds that can be vaccinated in the coming years,” he said.

Health Minister Bent Hoeie said in a press conference: “The government will take this as a basis for deciding whether to use these vaccines, along with the recommendations of the Institute of Public Health.”

He did not say when the government would make the decision.

The FHI on Monday cited the same strange reactions to the reason for advising against the use of J&J shooting.

AstraZeneca said it is awaiting a final decision from the Norwegian government.

“We will continue to work with regulators and local authorities to provide all available data to inform them of the decisions,” he told Reuters in a statement to the news agency.

Johnson & Johnson did not immediately respond to a request for comment.

First dose

Although the EMA said the benefits of AstraZeneca’s cheap and easy-to-transport vaccine outweigh the risks, many European countries have limited use for older ages. EMA has opted for the J&J vaccine, which is based on a technology similar to AstraZeneca.

Norway currently only uses vaccines developed by Moderna and Pfizer-BioNTech.

The FHI said infection rates were under control in Norway and 90% of people aged 65 and over received their first vaccine dose.

Authorities expect all adults to be shot first by July 25, even without using the AstraZeneca and J&J vaccines.

Denmark has excluded AstraZeneca and J&J shots from the vaccination program. In contrast, Germany said on Monday that it would make the J&J plans available to all adults.